Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams purchased 48,100 shares of Vivani Medical stock in a transaction dated Friday, November 13th. The shares were bought at an average cost of $0.99 per share, for a total transaction of $47,619.00. Following the transaction, the director directly owned 36,960,836 shares of the company’s stock, valued at approximately $36,591,227.64. The trade was a 0.13% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Gregg Williams also recently made the following trade(s):
- On Tuesday, November 17th, Gregg Williams purchased 29,929 shares of Vivani Medical stock. The stock was purchased at an average price of $1.05 per share, with a total value of $31,425.45.
- On Monday, November 16th, Gregg Williams acquired 2,100 shares of Vivani Medical stock. The stock was purchased at an average cost of $1.01 per share, with a total value of $2,121.00.
Vivani Medical Price Performance
Shares of NASDAQ VANI opened at $1.05 on Thursday. The stock’s 50 day moving average price is $1.16 and its two-hundred day moving average price is $1.23. Vivani Medical, Inc. has a 52-week low of $0.80 and a 52-week high of $1.66. The stock has a market capitalization of $94.71 million, a P/E ratio of -3.28 and a beta of 2.51.
Vivani Medical (NASDAQ:VANI – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01.
Wall Street Analyst Weigh In
VANI has been the topic of several research analyst reports. Wall Street Zen cut Vivani Medical from a “hold” rating to a “sell” rating in a research note on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Vivani Medical presently has a consensus rating of “Hold” and an average target price of $3.75.
Check Out Our Latest Research Report on Vivani Medical
About Vivani Medical
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
Featured Articles
- Five stocks we like better than Vivani Medical
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
